よむ、つかう、まなぶ。
04資料２ 新型コロナワクチンに関する資料 (82 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00026.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会（第51回 1／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Against
Covid-19.
medRxiv,
2022.2012.2011.22283166
(2022).
https://doi.org:10.1101/2022.12.11.22283166
63
Atmar, R. L. et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl
J Med 386, 1046-1057 (2022). https://doi.org:10.1056/NEJMoa2116414
64
Munro, A. P. S. et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and
mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of
ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a
multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis 22, 1131-1141 (2022).
https://doi.org:10.1016/s1473-3099(22)00271-7
65
Lazarus, R. et al. Safety and immunogenicity of concomitant administration of COVID19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the
UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 398,
2277-2287 (2021). https://doi.org:10.1016/S0140-6736(21)02329-1
66
Toback, S. et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVXCoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a
randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med 10,
167-179 (2022). https://doi.org:10.1016/S2213-2600(21)00409-4
67
Izikson, R. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine
administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in
adults aged >/=65 years: a phase 2, randomised, open-label study. Lancet Respir Med 10,
392-402 (2022). https://doi.org:10.1016/S2213-2600(21)00557-9
68
Hause, A. M. et al. Reactogenicity of Simultaneous COVID-19 mRNA Booster and
Influenza Vaccination in the US. JAMA Netw Open 5, e2222241 (2022).
https://doi.org:10.1001/jamanetworkopen.2022.22241
82
Covid-19.
medRxiv,
2022.2012.2011.22283166
(2022).
https://doi.org:10.1101/2022.12.11.22283166
63
Atmar, R. L. et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl
J Med 386, 1046-1057 (2022). https://doi.org:10.1056/NEJMoa2116414
64
Munro, A. P. S. et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and
mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of
ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a
multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis 22, 1131-1141 (2022).
https://doi.org:10.1016/s1473-3099(22)00271-7
65
Lazarus, R. et al. Safety and immunogenicity of concomitant administration of COVID19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the
UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 398,
2277-2287 (2021). https://doi.org:10.1016/S0140-6736(21)02329-1
66
Toback, S. et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVXCoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a
randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med 10,
167-179 (2022). https://doi.org:10.1016/S2213-2600(21)00409-4
67
Izikson, R. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine
administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in
adults aged >/=65 years: a phase 2, randomised, open-label study. Lancet Respir Med 10,
392-402 (2022). https://doi.org:10.1016/S2213-2600(21)00557-9
68
Hause, A. M. et al. Reactogenicity of Simultaneous COVID-19 mRNA Booster and
Influenza Vaccination in the US. JAMA Netw Open 5, e2222241 (2022).
https://doi.org:10.1001/jamanetworkopen.2022.22241
82